GARS1 and stiff-person syndrome: The combination of slow pharmacokinetics and a broad therapeutic window is useful for systemically acting drugs. In vivo protection of GlyRs may be therapeutically relevant in the treatment of glycine receptor-associated motor disorders, such as hyperekplexia, stiff man syndrome, and other convulsant diseases.